Table 4.
Current recommendations for corticosteroid use in subjects with ARDS
| Guideline (reference) | SCCM/ESICM [20] | BTS/ICM/ICSGDG [21] | JPCG [23] | SRLF [22] |
|---|---|---|---|---|
| Indication | Moderate-to-severe ARDS | Mild-to-severe ARDS | Not specified | Moderate-to-severe ARDS |
| Drug | Methylprednisolone | Not specified | Methylprednisolone | Methylprednisolone |
| Daily dose | 1 mg/kg | Not specified | 1–2 mg/kg | 1 mg/kg |
| Duration | 14 daysa | Not specified | At least 7 days | 14 daysa |
| Tapering | Yes, over 14 days | Not specified | Not specified | Yes |
| Degree of recommendation | Conditional | Further research | Conditional | Conditional |
| Strength of evidence | Moderate | Low–very low | Low–very low | Not specified |
| Year | 2017 | 2019 | 2021 | 2019 |
aIn the presence of persistent ARDS the daily dose of methylprednisolone should be increased to 2 mg/kg